Latest News on HAE

Financial News Based On Company


Advertisement
Advertisement

Haemonetics receives CE mark for vascular closure system

https://www.investing.com/news/company-news/haemonetics-receives-ce-mark-for-vascular-closure-system-93CH-5035515
Haemonetics Corporation announced it has received CE Mark certification for its VASCADE MVP XL venous vascular closure system, allowing it to be marketed in the European Union and other regions recognizing CE marking. This device is designed for procedures requiring larger sheaths and is an enhancement to their existing vascular closure portfolio, which has contributed to the growth of their Interventional Technologies business. The first European procedures using this system were successfully performed in Germany, Italy, and the UK in October.

Haemonetics' VASCADE MVP XL Secures CE Mark, Begins European Commercial Use

https://kalkinemedia.com/us/news/announcements/haemonetics-vascade-mvp-xl-secures-ce-mark-begins-european-commercial-use
Haemonetics Corporation announced that its VASCADE MVP XL venous vascular closure system has received CE Mark certification under EU-MDR, allowing its commercialization in Europe. The initial procedures have been successfully performed in Germany, Italy, and the UK. This system, designed for various catheter-based procedures, offers benefits such as reduced time to ambulation and discharge eligibility compared to traditional closure methods.

Form 144 HAEMONETICS CORP For: 14 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-haemonetics-corp-for-14-november-93CH-5704964
This article announces the filing of Form 144 for HAEMONETICS CORP on November 14. Form 144 is a notice of the intent to sell restricted securities. The article provides this information along with market data and related financial news.

Form 144 HAEMONETICS CORP For: 14 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-haemonetics-corp-for-14-november-93CH-4982887
This article announces the filing of Form 144 for HAEMONETICS CORP on November 14. The brief piece indicates that this filing is a standard regulatory disclosure without providing further details on the nature of the transaction. It was published by Investing.com.

Option exercises accompany Haemonetics (HAE) accounting chief's share sale averaging $120.99.

https://www.stocktitan.net/sec-filings/HAE/form-4-haemonetics-corp-insider-trading-activity-63cf72a00db4.html
Haemonetics Corp.'s VP, Chief Accounting Officer, Farris Maryanne Maunsell, exercised options for 2,146 shares at various prices and subsequently sold 836 shares at a weighted average price of $120.99. These transactions, reported on November 11, 2026, also included the withholding of 1,724 shares for tax or exercise price obligations. No Rule 10b5-1 plan was reported in connection with these insider trades.
Advertisement

Jefferies initiates Haemonetics stock with buy rating on growth outlook

https://www.investing.com/news/analyst-ratings/jefferies-initiates-haemonetics-stock-with-buy-rating-on-growth-outlook-93CH-5024333
Jefferies has initiated coverage on Haemonetics Corp. (NYSE:HAE) with a buy rating and a $150 price target, citing the company's diversified medical technology, defensible technology moat in plasma, and recurring growth engines in its medical surgery segment. The firm anticipates strong revenue and EPS growth with multiple paths to upside in fiscal year 2027. This positive outlook is supported by recent strong Q2 fiscal 2027 earnings and revenue that exceeded analyst expectations, leading other firms like BTIG and Mizuho to also raise their price targets.

A proposed $101K sale covers 836 Haemonetics (HAE) shares held by officer Maryanne Farris.

https://www.stocktitan.net/sec-filings/HAE/144-haemonetics-corp-sec-filing-a9c281cde9a4.html
Haemonetics officer Maryanne Farris has proposed selling 836 common shares, valued at approximately $101,144.38, with an approximate sale date of November 11, 2026. The shares to be sold were acquired through restricted stock vesting on various dates in 2024 and 2025, and a stock option exercise on November 11, 2026. This proposed sale was filed with the SEC on November 12, 2026, and is considered to have a neutral filing impact and sentiment.

Will Raised Revenue Guidance Change Haemonetics Stock Narrative

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/will-raised-revenue-guidance-change-haemonetics-stock-narrat
Haemonetics reported strong Q2 fiscal 2027 results, with sales of US$357.76 million and net income of US$46.31 million, leading to an increase in its full-year revenue growth guidance to 8-11%. This positive outlook is driven by organic revenue growth across its key segments and new regulatory clearances, reinforcing a narrative of recurring, procedure-linked revenue streams. The company's ability to maintain this growth amidst cost pressures and a significant debt load will be crucial for its sustained profitability and investor confidence.

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded CSL ...

https://sg.finance.yahoo.com/news/haemonetics-corp-hae-q2-2027-091243102.html
Haemonetics Corp (HAE) reported strong organic revenue growth of 10% in Q2 and 8% in H1 FY27, with adjusted EPS up 6% in both periods, leading to raised fiscal 2027 revenue guidance. The company also announced an expanded partnership with CSL, which is expected to drive significant multi-year growth, particularly in plasma revenue. Despite strong top-line performance, adjusted operating margins saw a slight decline due to increased performance-based compensation, elevated production costs, and investments related to the CSL rollout.

Mizuho raises Haemonetics stock price target on plasma strength By Investing.com

https://ca.investing.com/news/stock-market-news/mizuho-raises-haemonetics-stock-price-target-on-plasma-strength-93CH-4935975
Mizuho increased its price target for Haemonetics Corp. (NYSE:HAE) shares to $165 from $140, maintaining an Outperform rating due to strong plasma acceleration and Apheresis guidance. The firm highlighted 18% organic growth in plasma, driven by volume and market share gains. Despite a slight reduction in fiscal year adjusted operating margin guidance due to CSL buildout, Mizuho anticipates further upside as plasma gains are not fully captured and other segments improve.
Advertisement

Haemonetics Shares Rose Even As Profit Fell

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/haemonetics-shares-rose-even-as-profit-fell
Haemonetics (NYSE: HAE) shares have risen by 59.3% year-to-date despite a recent dip in net income, trading now at US$127. While a bullish narrative initially pegged fair value at US$108 due to recurring technology revenue and wider margins, a more cautious view suggested US$65.5 due to market pressures. The current share price implies a continuation of recent revenue growth and margin expansion, which may leave limited room for disappointment if cost pressures intensify.

A live webcast at 8 a.m. ET on Nov. 5 will cover Haemonetics' second-quarter results

https://www.stocktitan.net/news/HAE/haemonetics-corporation-announces-second-quarter-fiscal-2027-qkazb53u2l7q.html
Haemonetics (NYSE: HAE) has announced that its second-quarter fiscal 2027 financial results are available on its Investor Relations website. The company will host a conference call and webcast on November 5, 2026, at 8:00 a.m. ET to discuss these results. A replay of the event will be accessible for one year starting at 11:00 a.m. ET on the same day.

Haemonetics 3Q 2026: Revenue $357.76M, EPS $1 — 10-Q Summary

https://www.tradingview.com/news/tradingview:a4664678db070:0-haemonetics-3q-2026-revenue-357-76m-eps-1-10-q-summary/
Haemonetics (HAE) reported significant year-over-year increases in second-quarter revenue and net income, driven by strong performance in its Plasma and MedSurg segments. Revenue rose 9.3% to $357.76 million, while diluted EPS increased 23.5% to $1. The company's gross profit margin also improved to 61.7%, reflecting favorable product mix and tariff refunds.

Revenue rises 9.3% at Haemonetics (HAE), with quarterly profit growing faster.

https://www.stocktitan.net/sec-filings/HAE/10-q-haemonetics-corp-quarterly-earnings-report-1c33ecfa1b8d.html
Haemonetics Corporation (HAE) reported a 9.3% increase in net revenue to $357.8 million for the three months ended September 26, 2026, with net income rising 19.7% to $46.3 million. The growth was primarily driven by volume increases and market share gains in its Apheresis Plasma and MedSurg's Hemostasis Management and Transfusion Management product lines. The company also detailed the acquisition of Vivasure Medical Limited for $166.0 million and the FDA approval of Vivasure's PerQseal Elite, alongside updates on its share repurchase program and credit facilities.

146 shares are withheld for vesting taxes from Haemonetics (HAE) commercial chief Roy Galvin.

https://www.stocktitan.net/sec-filings/HAE/form-4-haemonetics-corp-insider-trading-activity-9681376b0550.html
Haemonetics Corp.'s EVP, Chief Commercial Officer Roy Galvin had 146 shares withheld for tax obligations due to the vesting of restricted stock units on October 30, 2026. The reported price per share was $119.65, and his direct holdings after this transaction totaled 39,805 shares, which includes unvested RSUs and 69 shares acquired through an employee stock purchase plan. This transaction, filed as a Form 4, indicates a neutral filing sentiment and impact.
Advertisement

Haemonetics Corp stock hits 52-week high at 124.57 USD

https://www.investing.com/news/company-news/haemonetics-corp-stock-hits-52week-high-at-12457-usd-93CH-4999971
Haemonetics Corp (HAE) stock recently hit a 52-week high of $124.57, trading just below its peak and considered undervalued by Fair Value analysis. The company has shown strong performance, with a 141.78% increase over the past year and significant gains year-to-date and over six months. Recent positive developments include exceeding fiscal first-quarter forecasts and a supply agreement with CSL Plasma Inc., leading to increased price targets from BTIG.

Haemonetics Corp (HAZ.MU) Seasonal returns chart

https://au.finance.yahoo.com/quote/HAZ.MU/seasonality/
This article from Yahoo Finance provides a seasonal returns chart for Haemonetics Corp (HAZ.MU), showing the average monthly price return from 2016 to 2026. It also notes the upcoming Q2 2027 earnings call for Haemonetics Corp on November 5, 2026. The stock was trading at 107.00 EUR at the close on November 2.

Haemonetics Corporation (HAE) Seasonal returns chart

https://uk.finance.yahoo.com/quote/HAE/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Haemonetics Corporation (HAE), showing the average monthly price return between 2016 and 2026. The article provides current stock performance data for HAE and other market indices. It also includes links to various financial data sections for the company.

Haemonetics Corp (HAZ.MU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/HAZ.MU/seasonality/
This article provides a historical seasonality chart for Haemonetics Corp (HAZ.MU), showing the average monthly price return from 2016 to 2026. The stock was quoted at 107.00 EUR at the close on October 30, 2026, with no change. The data is presented by Yahoo Finance.

Haemonetics (HAE) Wins FDA Approval, Is The Stock Fairly Valued?

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/haemonetics-hae-wins-fda-approval-is-the-stock-fairly-valued
Haemonetics (HAE) recently secured FDA approval for its PerQseal Elite vascular closure system, bolstering its hospital technology offerings after the Vivasure Medical acquisition. The stock has seen significant momentum, with a 1-year return of 132.75%, but despite this rally, it remains modestly undervalued at $119.19 compared to a fair value of $124.50, driven by strong financial performance and portfolio transformation. Investors are now evaluating the long-term impact of these developments on the company's growth and risk profile.
Advertisement

All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy

https://ca.finance.yahoo.com/news/know-haemonetics-hae-rating-upgrade-150005411.html
Haemonetics (HAE) has received an upgrade to a Zacks Rank #2 (Buy), reflecting a positive shift in its earnings outlook. This upgrade is based on upward trends in earnings estimates, which are a strong indicator of future stock price movements. The Zacks Rank system, which correlates earnings estimate revisions with stock performance, suggests that Haemonetics' improving business fundamentals could lead to an increase in its stock price.

What Haemonetics Holders Saw Early

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/what-haemonetics-holders-saw-early
Haemonetics shareholders saw a 48.2% return year-to-date, fueled by optimism around plasma growth and hospital technology. Despite strong revenue, Q1 2027 net income and net margin declined, presenting a mixed picture. The current stock price of US$119, above a Narrative's Fair Value, suggests buyers are confident in continued growth and margin expansion despite potential cost pressures.

Could FDA Approval Change The Bull Case For Haemonetics (HAE)?

https://simplywall.st/stocks/us/healthcare/nyse-hae/haemonetics/news/could-fda-approval-change-the-bull-case-for-haemonetics-hae
Haemonetics (HAE) recently received FDA approval for its PerQseal Elite vascular closure system, which could strengthen its interventional technologies segment. This new product, acquired with Vivasure Medical, broadens Haemonetics' portfolio and supports its goal of increasing disposable volume and improving operating leverage. While the approval itself doesn't immediately reset the near-term outlook, it contributes to the company's long-term strategy of steady recurring revenue and healthier margins, alongside growth in its plasma and TEG platforms.

BTIG Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $130

https://www.moomoo.com/news/post/1001704929/btig-maintains-haemonetics-haeus-with-buy-rating-maintains-target-price
BTIG has reaffirmed its Buy rating on Haemonetics (HAE.US) and maintained a target price of $130. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Mizuho raised target for Haemonetics stock to USD 140.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mizuho-raised-target-for-haemonetics-stock-to-usd-140-00/70377004
Mizuho increased its price target for Haemonetics (HAE) stock from $95.00 to $140.00, citing updated terms for Haemonetics equipment and disposable products at CSL Plasma. This revised target is based on CSL's plan to convert all its U.S. centers to Haemonetics equipment by the end of 2027. Haemonetics is set to release its fiscal second-quarter 2027 results on November 5, 2026.
Advertisement

FDA Clears Haemonetics PerQseal Elite Vascular Closure System

https://www.clinicaltrialvanguard.com/news/fda-clears-haemonetics-perqseal-elite-vascular-closure-system/
The FDA has approved Haemonetics' PerQseal Elite vascular closure system for large-bore arterial procedures, following a prospective multicenter trial that reported 0% major complications. This system uses a fully bioabsorbable patch and allows for confirmation of hemostasis while maintaining guidewire access, offering a sutureless alternative to existing closure methods. Haemonetics acquired Vivasure Medical in January 2026, with PerQseal Elite being the key asset justifying the acquisition price.

Haemonetics says FDA clears vascular closure device

https://www.reuters.com/legal/litigation/haemonetics-says-fda-clears-vascular-closure-device-2026-10-19/
Haemonetics announced that the U.S. FDA has approved its new vascular closure device, PerQseal Elite, which is designed to seal arterial openings in minimally invasive heart and vascular procedures. The device uses an absorbable patch and was acquired through Haemonetics' January 2026 acquisition of Vivasure Medical. Haemonetics' shares rose about 1.2% in extended trading following the announcement.

FDA approves Haemonetics' PerQseal Elite for large-bore arterial closure in the U.S.

https://pluang.com/en/news-feed/haemonetics-mendapatkan-persetujuan-fda-untuk-perqseal-elite
Haemonetics Corporation has received FDA approval for its PerQseal Elite vascular closure system, designed for large-bore arterial procedures. This sutureless, bioabsorbable device aims to improve patient outcomes and procedural efficiency with near-instantaneous hemostasis and no permanent implant. The approval follows successful clinical trials and positions Haemonetics to expand its advanced vascular closure technology in the U.S.

Haemonetics receives FDA approval for vascular closure device

https://www.investing.com/news/company-news/haemonetics-receives-fda-approval-for-vascular-closure-device-93CH-4958266
Haemonetics Corporation has received FDA approval for its PerQseal Elite vascular closure system, expanding its offerings for large-bore arterial procedures. The device, acquired with Vivasure Medical Limited, uses a bioabsorbable patch for sutureless closure and has shown 0% major complications in studies. This approval marks a significant step in Haemonetics' strategy for growth in advanced vascular closure.

Haemonetics Corporation (HAE) Wins FDA Approval for PerQseal Elite

https://www.tradingview.com/news/tradingview:ade562eb5b537:0-haemonetics-corporation-hae-wins-fda-approval-for-perqseal-elite/
Haemonetics Corporation (HAE) has received FDA approval for its PerQseal Elite vascular closure system, designed for large-bore arterial procedures. This approval expands Haemonetics' U.S. portfolio, following its acquisition of Vivasure in 2026, and is expected to drive growth in the structural heart and endovascular markets. The system's sutureless, bioabsorbable patch design and strong safety data from the ELITE study position it as a significant advancement for procedures like TAVR.
Advertisement

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

https://www.prnewswire.com/news-releases/haemonetics-announces-fda-approval-of-perqseal-elite-vascular-closure-system-302913028.html
Haemonetics Corporation announced that its PerQseal® Elite vascular closure system has received FDA approval for large-bore arterial procedures. This approval expands Haemonetics' portfolio in advanced vascular closure, offering a sutureless system with a fully bioabsorbable patch that seals arteriotomies up to 26F, enabling near-instantaneous hemostasis. The system is designed to simplify minimally invasive procedures like TAVR and has shown 0% major complications in clinical studies.

A study found an artery-sealing device stopped bleeding in under a minute on average. FDA approved it.

https://www.stocktitan.net/news/HAE/haemonetics-announces-fda-approval-of-per-qseal-elite-vascular-1owknta9f0g2.html
Haemonetics (NYSE: HAE) has received FDA approval for its PerQseal Elite vascular closure system, expanding its U.S. portfolio for large-bore arterial procedures. The system, which uses a fully bioabsorbable patch, demonstrated 0% major complications and a mean time to hemostasis of less than one minute in the ELITE arterial study. This approval follows the company's acquisition of Vivasure Medical and strengthens its presence in advanced vascular closure.

Haemonetics Gets US FDA Approval for PerQseal Elite Vascular Closure System

https://finance.yahoo.com/healthcare/articles/haemonetics-gets-us-fda-approval-210030133.html
Haemonetics (HAE) has received approval from the US Food and Drug Administration (FDA) for its PerQseal Elite Vascular Closure System. The article, however, requires a premium subscription to read the full details of this development.

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

https://finance.yahoo.com/healthcare/articles/haemonetics-gains-149-3-whats-111400608.html
Haemonetics (HAE) shares have surged 149.3% over the past year, driven by strong demand in its Plasma franchise and growth in its MedSurg business. The company's fiscal first-quarter 2027 revenues showed significant increases in both segments, leading to an upward revision of its fiscal 2027 revenue guidance. Despite strong performance, the company faces challenges including a highly leveraged balance sheet and competition in the market.

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?

https://sg.finance.yahoo.com/news/haemonetics-gains-149-3-whats-111400608.html
Haemonetics (HAE) has seen a significant 149.3% increase in its stock price over the past year, driven by strong demand in its Plasma franchise and growth in its MedSurg business. The company's Plasma revenues rose 7.2% and MedSurg revenues increased 6.0% in Q1 fiscal 2027. Despite a highly leveraged balance sheet with $1.17 billion in long-term debt, Haemonetics raised its fiscal 2027 revenue growth guidance.
Advertisement

Mizuho lifts target for Haemonetics stock to USD 140.00 with 15.57 percent upside opportunity

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mizuho-lifts-target-for-haemonetics-stock-to-usd-140-00-with-15-57-percent/70332858
Mizuho analyst Anthony Petrone raised the price target for Haemonetics (HAE) stock to USD 140.00 from USD 95.00, implying a 15.57% upside opportunity. The company is set to report its second-quarter fiscal year 2027 results on November 5, 2026, which will be a key event for investors. Haemonetics' stock was trading near its 52-week high, with a market capitalization of USD 5.5 billion and a trailing P/E ratio of 59.34 as of October 15, 2026.

Mizuho lifts target for Haemonetics stock to USD 140.00 with 15.57 percent upside opportunity

https://www.ad-hoc-news.de/boerse/news/nebenwerte/mizuho-lifts-target-for-haemonetics-stock-to-usd-140-00-with-15-57-percent-upside-opportunity/70332858
Mizuho analyst Anthony Petrone has raised the price target for Haemonetics (HAE) stock to USD 140.00 from USD 95.00, representing a 15.57% upside from its current trading price. This revised target comes ahead of the company's second-quarter fiscal year 2027 results, scheduled for November 5, 2026. Haemonetics, with a market capitalization of USD 5.5 billion, is currently trading near its 52-week high, and its upcoming earnings report will be a key indicator for market validation of the increased analyst targets.

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?

https://www.tradingview.com/news/zacks:013486aab094b:0-is-it-apt-to-retain-haemonetics-stock-in-your-portfolio-for-now/
Haemonetics (HAE) is poised for growth due to its impressive MedSurg business and the robust uptake of its NexSys PCS system. Despite competitive pressures and unfavorable foreign exchange impacting operations, the company has outperformed its industry and the S&P 500, with a strong earnings surprise history. The article suggests that its MedSurg portfolio, recent acquisitions, and advancements in plasma collection technology are key growth drivers, while also acknowledging potential risks from competition and currency fluctuations.

Haemonetics Corporation (HAE) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3737_QuantitativeReport_1791936000000
The article provides a title related to stock forecasts for Haemonetics Corporation (HAE) but the main content indicates an error in data retrieval. The page largely consists of navigation links, market data, and disclaimers rather than specific stock forecast information.

Haemonetics (HAE) Jumped, What Is Behind The Move?

https://finance.yahoo.com/markets/stocks/articles/haemonetics-hae-jumped-behind-move-050955622.html
Haemonetics (HAE) shares jumped over 13% after CSL Plasma committed to deploying Haemonetics' NexSys PCS devices across all US plasma centers by late 2027. This latest surge adds to significant prior gains, with the company showing strong financial performance and a richer mix of disposables and software contributing to improved margins and cash flow. While some analysts view the stock as overvalued, a discounted cash flow model suggests it might be undervalued.
Advertisement

Haemonetics Corporation (HAE) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3737_QuantitativeReport_1791331200000?ref=bullished.co
Argus has lowered its target price for Haemonetics Corp (HAE) to $109.00, while the current price stands at $118.69. The company focuses on providing medical products and solutions for blood and plasma component collection, surgical suites, and hospital transfusion services. The report suggests upgrading for premium research and additional insights.

Haemonetics (HAE) Stock Climbs After Citi Ups Price Target

https://timothysykes.com/news/haemonetics-corporation-hae-news-2026_10_08-2/
Haemonetics (HAE) stock has climbed by 16.93% after Citigroup upgraded its rating from Neutral to Buy and raised its price target from $92 to $123. This upgrade is largely driven by anticipated earnings upside from Haemonetics' new non-exclusive CSL supply deal and the ongoing progress of its Vivasure acquisition. Traders are closely watching HAE, particularly with its Q2 FY2027 earnings call scheduled for November 5, 2026, which will provide further updates on these strategic initiatives.

What Moved Humana (NYSE:HUM), Alignment Healthcare (NASDAQ:ALHC), Haemonetics (NYSE:HAE) and XLV (NYSEARCA:XLV) on October 8?

https://kalkine.ca/news/healthcare/what-moved-humana-nysehum-alignment-healthcare-nasdaqalhc-haemonetics-nysehae-and-xlv-nysearcaxlv-on-october-8-1
On October 8, Humana (NYSE:HUM) saw a significant increase in stock value after its largest Medicare Advantage contract received a 4-star rating from CMS, making it eligible for bonus payments. Conversely, Alignment Healthcare (NASDAQ:ALHC) experienced a sharp decline as its California contract, representing most of its membership, dropped to a 3.5-star rating, impacting its bonus eligibility. Haemonetics (NYSE:HAE) surged due to an updated supply agreement with CSL Plasma for its NexSys PCS devices, while the broader Health Care Select Sector SPDR Fund (NYSEARCA:XLV) generally declined despite a landmark FDA approval for Roche's Tecentriq.

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

https://finance.yahoo.com/markets/stocks/articles/strength-seen-haemonetics-hae-17-104300839.html
Haemonetics (HAE) shares surged 17.5% after CSL announced plans to complete the rollout of Haemonetics' devices across its U.S. plasma collection centers by the end of 2027. While the company expects quarterly earnings growth of 2.4% and revenue growth of 6%, the lack of recent earnings estimate revisions suggests the stock's upward momentum might not be sustained without further positive developments. Investors are advised to monitor HAE for future strength.

Haemonetics stock hits 52-week high at 114.0 USD

https://www.investing.com/news/company-news/haemonetics-stock-hits-52week-high-at-1140-usd-93CH-4939221
Haemonetics (HAE) stock reached a new 52-week high of $110.45, with shares currently trading at $113.05, representing a 102.81% increase over the past year. This surge is attributed to strong investor confidence and robust financial performance. Recent developments include a supply agreement with CSL Plasma Inc. and better-than-expected fiscal first-quarter results, leading BTIG to raise its price target for the company.
Advertisement

BTIG raises Haemonetics stock price target on CSL Plasma deal

https://www.investing.com/news/analyst-ratings/btig-raises-haemonetics-stock-price-target-on-csl-plasma-deal-93CH-4939301
BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $130 from $110, maintaining a Buy rating, following new details regarding Haemonetics' supply agreement with CSL Plasma Inc. CSL Plasma plans to transition all its U.S. plasma collection centers to Haemonetics' NexSys PCS devices with Persona PLUS technology by the end of 2027. Despite the surge in shares, InvestingPro analysis indicates the stock remains undervalued, with net income expected to grow this year.

A rollout to all current U.S. CSL plasma centers is anticipated for Haemonetics (HAE), subject to change.

https://www.stocktitan.net/sec-filings/HAE/8-k-haemonetics-corp-reports-material-event-b2d8d0fcc32d.html
Haemonetics Corporation (HAE) announced that CSL Plasma expects to complete the rollout of Haemonetics' NexSys PCS® devices with Persona® PLUS technology to all its U.S. plasma collection centers by the end of calendar year 2027. The scope and timing of this non-exclusive supply agreement are subject to change, and Haemonetics is not updating its fiscal 2027 guidance at this time, but plans to provide an update in November 2026. This information was disclosed in an 8-K filing, detailing key aspects of the agreement and its anticipated impact.

Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123

https://timothysykes.com/news/haemonetics-corporation-hae-news-2026_10_08-3/
Haemonetics (HAE) shares surged by 17.46% after Citigroup upgraded the stock from Neutral to Buy and increased its price target to $123 from $92. This upgrade is largely driven by a new non-exclusive supply agreement with CSL, which Citi estimates could add $0.13 to EPS for every 10% share recapture. Traders are now watching for Haemonetics' Q2 FY2027 results on November 5, 2026, as the next major catalyst to confirm the optimistic outlook.

Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123

https://stockstotrade.com/news/haemonetics-corporation-hae-news-2026_10_08-3/
Haemonetics (HAE) stock saw a significant jump after Citigroup upgraded its rating from Neutral to Buy and raised its price target to $123, citing potential earnings upside from a new CSL supply deal. The company also announced a milestone payment related to its Vivasure acquisition, with future earnouts tied to revenues, indicating strategic growth alongside near-term catalysts. Traders are now watching HAE for continued momentum, especially with its upcoming Q2 FY2027 results on November 5, 2026.

Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside

https://stockstotrade.com/news/haemonetics-corporation-hae-news-2026_10_08-2/
Haemonetics Corporation (HAE) saw its stock climb by 16.93% following strong earnings and guidance, further boosted by a Citigroup upgrade from Neutral to Buy. Citi raised its price target to $123, citing potential earnings upside from a new non-exclusive supply agreement with CSL and progress on the Vivasure acquisition. The company's Q2 FY2027 earnings call on November 5, 2026, is anticipated as the next key catalyst for traders.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement